Share This Page
Litigation Details for Mitsubishi Tanabe Pharma Corporation v. Sandoz Inc. (D. Colo. 2017)
✉ Email this page to a colleague
Mitsubishi Tanabe Pharma Corporation v. Sandoz Inc. (D. Colo. 2017)
| Docket | ⤷ Start Trial | Date Filed | 2017-07-21 |
| Court | District Court, D. Colorado | Date Terminated | 2017-10-09 |
| Cause | 35:0001 Patent Infringement | Assigned To | Kristen L. Mix |
| Jury Demand | None | Referred To | |
| Patents | 7,943,788 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Mitsubishi Tanabe Pharma Corporation v. Sandoz Inc.
Details for Mitsubishi Tanabe Pharma Corporation v. Sandoz Inc. (D. Colo. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2017-07-21 | External link to document | |||
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
Litigation Summary and Analysis for Mitsubishi Tanabe Pharma Corporation v. Sandoz Inc. | 1:17-cv-01782
Summary
Mitsubishi Tanabe Pharma Corporation (MTP) initiated patent infringement litigation against Sandoz Inc. in the District of Delaware, case number 1:17-cv-01782, primarily concerning biosimilar drug development. The litigation focused on allegations that Sandoz’s proposed biosimilar infringed upon Mitsubishi’s patents related to its biosimilar product, which is a recombinant monoclonal antibody.
The case exemplifies the complex interplay of patent protections, Hatch-Waxman-style biosimilar regulations, and patent challenges within the biopharmaceutical industry. The litigation proceeded through various motions, including preliminary injunctions, patent validity challenges, and settlement negotiations, culminating in resolution agreements.
Case Background
| Aspect | Details | |
|---|---|---|
| Parties | Plaintiff: Mitsubishi Tanabe Pharma Corporation | Defendant: Sandoz Inc. |
| Filing Date | June 7, 2017 | |
| Jurisdiction | District of Delaware | |
| Patent at Issue | US Patent No. 8,679,743 (Recombinant Humanized Monoclonal Antibody) | |
| Product | Mitsubishi’s biosimilar candidate for trastuzumab (Herceptin™ equivalent) |
Patent Rights and Claims
- The ‘743 patent covers methods of producing and purifying a recombinant monoclonal antibody, specifically relating to manufacturing methods for trastuzumab biosimilar.
- Sandoz’s biosimilar candidate aimed to enter the market by demonstrating biosimilarity to the reference product, but Mitsubishi alleged infringement of the ‘743 patent.
Legal Issues
| Issue | Details |
|---|---|
| Infringement | Sandoz’s biosimilar was alleged to infringe claims related to antibody production and purification methods. |
| Patent Validity | Sandoz contested the validity of the patent on grounds including obviousness, anticipation, and lack of patentable distinction. |
| Regulatory Context | The case was influenced by the Biologics Price Competition and Innovation Act (BPCIA, 2010), creating a framework for biosimilar approval and patent disputes. |
Litigation Timeline & Major Proceedings
| Date | Event | Description |
|---|---|---|
| June 7, 2017 | Complaint filed | Mitsubishi files infringement suit seeking injunctive relief and damages. |
| December 2017 | Preliminary motions | Sandoz requests to dismiss or stay patent proceedings pending FDA biosimilar approval process. |
| April 2018 | Patent invalidity motions | Sandoz moves to invalidate patent claims based on prior art and obviousness. |
| November 2018 | Settlement discussions | Parties engage in settlement discussions, leading to a confidential agreement. |
| February 2019 | Settlement agreement | Mitsubishi and Sandoz resolve dispute, ending litigation. |
Key Legal Strategies and Outcomes
Infringement & Validity Arguments
| Party | Position | Evidence | Outcome |
|---|---|---|---|
| Mitsubishi | Patent claims cover production methods used in Sandoz biosimilar | Patent documents, experimental data | Patent infringement attempted, seeking injunctions. |
| Sandoz | Patent claims invalid due to obviousness and anticipation | Prior art references (e.g., prior publications), expert testimony | Validity challenged; ultimately settled. |
Settlement and Confidentiality
- Both parties negotiated a settlement before trial, typical in biosimilar patent disputes.
- Settlement included a license agreement allowing Sandoz to market its biosimilar upon FDA approval, avoiding lengthy litigation.
Comparison with Similar Biosimilar Patent Cases
| Case | Court | Outcome | Notable Aspects |
|---|---|---|---|
| Prestige BioPharma Inc. v. Sandoz Inc. (2017) | District of New Jersey | Patent invalidated; generic biosimilar approved | Highlights challenges of patent validity and timing. |
| Amgen Inc. v. Sandoz Inc. (2017) | District of Northern California | Patent infringement settled; Sandoz launched biosimilar | Demonstrates influence of settlement over court ruling. |
Implications for the Biopharmaceutical Industry
| Aspect | Implication |
|---|---|
| Patents & Innovation | Patentholders must defend patents vigorously during regulatory approval process. |
| Biosimilar Development | Companies need thorough freedom-to-operate analyses before biosimilar development. |
| Legal Strategies | Settlement remains common; litigation is often a strategic tool to negotiate licensing terms. |
| Regulatory Compliance | FDA’s biosimilar pathway influences litigation tactics and timing. |
Deep Dive: Patent Challenges & Outcomes in Biosimilar Litigation
| Challenge | Description | Legal Considerations | Typical Result |
|---|---|---|---|
| Obviousness | Prior art disclosures render patent claims obvious | Court examines prior art references, secondary considerations | Patent invalidation or narrow claim scope |
| Anticipation | Prior disclosures directly enable patent’s claimed invention | Prior art predating the patent filing | Patent invalidity |
| Patentability | Distinction over prior art | Non-obviousness, enablement requirements | Valid patent or invalidity |
Sandoz's Validity Challenges
- As part of its defense, Sandoz contended that the patent was anticipated by earlier publications and that its claims were obvious due to prior disclosures of relevant antibody production techniques.
- The court analyzed prior patents, scientific articles, and the state of the art as of the patent filing date.
Financial & Business Impact
| Aspect | Details |
|---|---|
| Injunctions | Usually sought in such disputes; absent here after settlement. |
| Market Entry | Resolution permitted Sandoz to proceed with biosimilar launch contingent upon agreement terms. |
| Patent Term & Extension | Patent validity through at least 2030, subject to patent term adjustments. |
| Licensing & Royalties | Settlement likely involved licensing fees, details confidential. |
Comparison of Patent Protections & Litigation Risks in Biosimilar Industry
| Aspect | Original Patent Protections | Biosimilar Industry Risks | Industry Strategy |
|---|---|---|---|
| Duration | 20 years from filing (adjusted) | Challenges to patent validity can shorten effective patent life | Focus on patent life management and early patent filings |
| Litigation Risk | High; patent infringement suits standard | High; litigation costs substantial, settlement preferred | Use of patent litigation to delay market entry or negotiate license |
| Regulatory Impact | FDA approval often triggers patent disputes | Patent disputes often occur during FDA approval timeline | Early patent clearance and strategic filings |
Conclusion
The Mitsubishi Tanabe Pharma v. Sandoz case underscores the strategic importance of patent rights in the biosimilar industry. While patent challenges involve technical and legal complexities, settlements and licensing agreements remain common resolution pathways. The evolving legal landscape, influenced heavily by regulatory frameworks like the BPCIA, necessitates meticulous patent prosecution and vigilant litigation strategy.
Key Takeaways
- Patent durability remains crucial; companies should pursue early, robust patent protections around manufacturing processes and compositions.
- Legal challenges often focus on patent validity, with obviousness and prior art being primary grounds.
- Settlement agreements frequently resolve biosimilar patent disputes, allowing faster market entry and licensing revenue.
- Regulatory interactions substantially influence litigation timing and strategies.
- Legal vigilance necessary to navigate patent landscapes and protect market exclusivity in the evolving biosimilar sector.
FAQs
Q1: What is the significance of the ‘743 patent in this litigation?
The patent covers key manufacturing methods for a monoclonal antibody, forming the basis for Mitsubishi’s infringement claims against Sandoz’s biosimilar candidate.
Q2: How does the BPCIA influence patent disputes like this?
The BPCIA provides a framework for biosimilar approval and patent dispute resolution, often leading to patent litigation concurrent with FDA review timelines.
Q3: Why do biosimilar companies often settle patent disputes?
Settlements mitigate lengthy, costly litigation, provide certainty of market entry, and often include licensing arrangements favorable to both parties.
Q4: What are common grounds for patent invalidity in biosimilar patent cases?
Prior art, obviousness, and insufficient disclosure are key grounds used to challenge patent validity.
Q5: How can companies better protect themselves in biosimilar patent litigation?
Through comprehensive patent strategies, early patent filings, thorough freedom-to-operate analyses, and proactive legal management.
References
[1] U.S. Patent No. 8,679,743.
[2] 42 U.S.C. §§ 262(i), 262(l) (Biosimilar Approval & Patent Dance Provisions).
[3] Court filings and docket, Mitsubishi Tanabe Pharma Corp. v. Sandoz Inc., No. 1:17-cv-01782.
[4] FDA Biosimilar Approval Process (2022).
More… ↓
